Introduction
Recent promising human results of immunotherapies to block immune checkpoints such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD-1) (1-3) illustrate the importance of targeting molecules that inhibit T cell-mediated antitumor immunity. However, the immunosuppressive tumor microenvironment hampers the success of various immunotherapies. There are several intracellular checkpoints with great potential as targets to promote potent antitumor immunity. STAT3, for example, has been shown to be a crucial signaling mediator in tumor-associated immune cells as well as in tumor cells (4) (5) (6) (7) . In tumor cells, STAT3 promotes tumor cell survival/proliferation, invasion, and immunosuppression (8) . In the tumor microenvironment, STAT3 is persistently activated in immune cells, including T cells (9, 10) . CD4 + Tregs can induce peripheral tolerance, suppressing CD8 + T cell functions in various diseases, including cancer (6, (11) (12) (13) (14) (15) . Activated STAT3 in T cells contributes to expanding tumorassociated CD4 + Tregs (6, 16) . Moreover, Stat3 -/-CD8 + T cells, both endogenous and adoptively transferred, mount potent antitumor immune responses compared with those with intact Stat3 (9) .
As a nuclear transcription factor lacking its own enzymatic activity, STAT3 is a challenging target for both antibody and smallmolecule drugs (8, 17, 18) . Recent pioneering work has shown the feasibility of delivering siRNA into tumor cells in vivo (19) . In particular, chimeric RNAs or DNA-RNAs consisting of a siRNA fused to nucleic acid sequences, which bind to either a cell-surface ligand or an intracellular receptor with high affinity, have demonstrated therapeutic efficacy in preclinical models (19) (20) (21) . The majority of such siRNA delivery technologies involves the fusion of siRNA to an aptamer, a structured RNA with high affinity to epitopes on tumor cells and virally infected epithelial cells. We recently described a technology for efficient in vivo delivery of siRNA into immune cells by linking an siRNA to CpG oligonucleotide, which binds to its cognate receptor, TLR9 (21) . TLR9 is expressed intracellularly in cells of myeloid lineage and B cells as well as tumor cells expressing TLR9, including human leukemic cells (21, 22) . However, the CpGsiRNA approach does not directly target T cells (21) .
Recently, an effective way of delivering siRNA into CD4 + T cells for local treatment of HIV has been developed (20) . However, for cancer immunotherapy, it is also crucial to regulate CD8 + effector T cells in addition to CD4 + cells. Further, it is quite plausible that selectively targeting the subpopulations of CD8 + and CD4 + T cells in the tumor microenvironment, rather than T cells in general, should afford more antitumor efficacy while reducing toxicity. The expression of CTLA4 is dysregulated in tumors and in tumorassociated T cells and is a promising immunotherapeutic target (23) . The broad antitumor immune response by CTLA4 blockade is thought to be mainly mediated by CD4 + T cells: reducing Tregs and increasing helper T cells (13, (24) (25) (26) (27) . However, activated/ exhausted CD8 + T cells also express CTLA4 (28) (29) (30) . In this study, we investigate the possibility that a CTLA4 apt might be able to deliver siRNA into both CD4 + and CD8 + T cells in the tumor milieu and in CTLA4-expressing tumor cells to silence intractable targets.
Results

CTLA4 apt -siRNA uptake and gene silencing in T cells.
We synthesized the CTLA4-targeting aptamer based on published sequences (23) and chemically modified it to protect its biostability (31-33); this was followed by linking it to a mouse STAT3 siRNA (Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/JCI73174DS1). We tested primary mouse splenic cells to assess specific uptake of the CTLA4 aptamer-STAT3 siRNA (CTLA4 apt -STAT3 siRNA) in immune cell populations in tumor. CD3 + T cells, including both CD8 + and CD4 + T cells that internalized the CTLA4 apt -STAT3 siRNA (FITC labeled), showed significant Stat3 gene silencing in vivo ( Figure 1A) . We isolated CD8 + T cells to confirm that CTLA4 apt -siRNA underwent cellular internalization and exerted a gene-silencing effect. Flow cytometry and live cell confocal microscopy indicated that CD8 + T cells internalized CTLA4 apt -siRNA in vitro (Figure 1 , B and C), trafficking vitro. Even though CTLA4 apt -STAT3 siRNA selectively internalized into CTLA4-expressing CD4 + and CD8 + T cells (Supplemental Figure 1 , B-D), macrophages and dendritic cells also took up the chimera in vivo, but to a lesser extent (Supplemental Figure 1E) . We then treated a progressive variant of fibrosarcoma tumors (34) with CTLA4 apt -STAT3 siRNA to assess the silencing efficiency of CTLA4 apt -STAT3 siRNA in various immune subsets within the siRNA. CD8-OTI cells were adoptively transferred into B16-OVA tumor-bearing Rag1 -/-mice, followed by CTLA4 apt -STAT3 siRNA and CTLA4 apt -LUC siRNA injections (all n = 4). CD8 + effector function was assessed analyzing granzyme B (GRB) and IFN-γ in ELISPOT assay. SD is shown. *P < 0.05; **P < 0.01; ***P < 0.001. (E) Improved T cell function of lymphocytes isolated from TDLNs after treating B16 melanoma tumor-bearing mice with CTLA4 apt -STAT3 siRNA or CTLA4 apt -LUC siRNA (all n = 4). ELISPOT was performed by recalling T cell responsiveness with B16 antigen-specific peptides. SD is shown. *P < 0.05; **P < 0.01, t test. (F) CD8 + T cell exhaustion was assessed by analyzing PD-1 expression upon treating tumor-bearing mice with indicated siRNA conjugates or vehicle control (all pools: n = 4). Gating on PD-1 + CD8 + T cells. ment of B16 tumors reduced PD-1 expression in tumor-associated CD8 + T cells, in contrast with CTLA4 apt -LUC siRNA or vehicle control treatment ( Figure 2F ), suggesting an improved CD8 + T cell effector population and an accumulated CTL response in vivo.
CTLA4 apt -STAT3 siRNA blocks tumor Treg accumulation and inhibits tumor growth. Since tumor-associated FoxP3 + Tregs are a major culprit in tumor-induced immunosuppression and highly express CTLA4 (11), we next tested the effects of CTLA4 apt -siRNA in targeting this population of T cells. CTLA4 apt -STAT3 siRNA treatment in Foxp3-GFP B16 tumor-bearing mice resulted in a significant reduction of FoxP3 + Tregs, shown by intravital multiphoton microscopy ( Figure 3A ). Flow cytometric analysis of CD4 + T cells isolated from tumors of B16 tumor-bearing mice confirmed a reduction in CD4 + CD25 + FoxP3 + Tregs ( Figure 3B ). Moreover, since IL-10 is one of the key mediators in suppression of T cell expansion by Tregs and a downstream target gene of STAT3, we evaluated IL-10 production by tumor-infiltrating Tregs. Results from this experiment showed that CTLA4 apt -STAT3 siRNA could effectively reduce tumor-associated Treg production of IL-10 ( Figure 3C ). However, monomeric CTLA4 apt treatment led to increased IL-10 expression that was abolished in vivo upon STAT3 siRNA delivery (Supplemental Figure 3) . We further tested whether CTLA4 apt -STAT3 siRNA could be systemically injected to achieve antitumor effects. Mice with B16 melanoma experimental lung metastases were treated systemically with CTLA4 apt -STAT3 siRNA, which led to a significant reduction of lung metastasis ( Figure 3D ). Furthermore, a drastic decrease of CD4 + Foxp3 + Tregs was observed, which was accompanied by loss of cell-to-cell contacts of Tregs to CD8 + T cells ( Figure 3E ). Conversely, infiltration of CD8 + T cells in metastatic lungs was significantly increased upon CTLA4 apt -STAT3 siRNA treatments ( Figure 3F ). Lung-infiltrating CD8 + T cells produced more granzyme B, supporting an active antitumor role of CD8 + T cells after systemic treatment of CTLA4 apt -STAT3 siRNA. In addition, T cells in the lung containing FITC-CTLA4 apt -STAT3 siRNA are CD3 + (Supplemental Figure 4) . The CD8 + subset of these cells had reduced PD-1 expression. (Figure 4A ). Moreover, CTLA4 apt -STAT3 siRNA but not CTLA4 apt -LUC siRNA uptake induced melanoma antigen-specific CD8 + T cells ( Figure 4B ) that produce IFN-γ ( Figure 4C ).
The ability of CTLA4 apt -STAT3 siRNA to silence Stat3 in both CD8 + and CD4 + T cells in the tumor suggested that CTLA4 apt -STAT3 siRNA treatment could induce a potent antitumor effect. In order to evaluate its therapeutic efficacy, we administered CTLA4 apt -STAT3 siRNA, CTLA4 apt -LUC siRNA, or vehicle control to mice bearing B16 melanoma, Renca renal cell carcinoma, A20 B cell lymphoma, or CT26 colon carcinoma tumors. Results from these experiments showed that CTLA4 apt -STAT3 siRNA treatments significantly reduced tumor growth in all 4 murine tumor models ( Figure 5 ).
Targeting human CTLA4 to deliver siRNA. The ligand-binding domain of CTLA4 represented by exon 2 coding for amino acids 117-153 harbors the consensus B7-binding motif MYPPPY, which is conserved in mouse and human (Supplemental Figure 5 ). This prompted us to assess CTLA4 apt internalization in human CTLA4 + T cell lymphoma cells. Using CTLA4 + Karpas299 T cell lymphoma ( Figure 6A ), we showed that the same CTLA4 apt used for siRNA delivery in mouse cells underwent efficient cellular internalization and colocalized with CTLA4 protein in the cytoplasm of the human T cells ( Figure 6B ). CTLA4 + human T cells efficiently internalize CTLA4 apt -STAT3 siRNA ( Figure 6C) , consistent with data shown in normal T cells (Supplemental Figure 1, C and D) . Although CD8 + T cells are known to express low levels of CTLA4, the biological functions of CTLA4 have mainly been characterized in CD4 + Tregs and Th cells (24, 26, 35) . We hypothesized that CTLA4 expression might be upregulated in CD8 + T cells in the tumor milieu. Because IL-6 is highly expressed in many tumors including the progressive fibrosarcoma (Supplemental Figure 2 , A and B) and was capable of inducing T cell tolerance in the tumorbearing mice (Supplemental Figure 2 , C-J), we tested whether IL-6 could upregulate CTLA4 expression. Flow cytometry showed an increase in CTLA4 protein expression in the tumor-draining LN (TDLN) (Figure 1G ), and confocal microscopy revealed that IL-6 treatment led to an accumulation of CTLA4 protein in lipid raft domains ( Figure 1, G and H) , suggesting a functional redistribution of CTLA4 on the surface of CD8 + T cells (36) (37) (38) .
CTLA4 apt -STAT3 siRNA improves CD8 + T cell effector responses in vivo. Using mice bearing B16 melanoma tumors, we first confirmed cellular internalization of CTLA4 apt -STAT3 siRNA in vivo by CD3 + T cells and their CD8 + subset isolated from TDLNs (Figure 2A) . Notably, CTLA4 apt -STAT3 siRNA uptake by CD8 + T cells was elevated in TDLNs compared with LNs from tumor-free mice, consistent with our hypothesis that tumor milieu/IL-6 upregulated CTLA4 expression, facilitating uptake of the RNA chimera (Figure 2A) . Moreover, CTLA4 apt -STAT3 siRNA administration in vivo resulted in efficient Stat3 knockdown in T cells compared with CTLA4 apt -LUC siRNA or vehicle control treatment (Figure 2 , B and C). To assess the antigen-specific CTL activity of tumor-associated CD8 + T cells, we adoptively transferred CD8 OT-I cells into Rag1 -/-mice bearing B16 OVA melanoma tumors. Antigen-specific production of granzyme B and IFN-γ by adoptively transferred CD8 OT-I cells was significantly enhanced upon CTLA4 apt -STAT3 siRNA treatment compared with treatment with CTLA4 apt -LUC siRNA, vehicle control, or CD8 OT-I alone ( Figure 2D ). Moreover, CTLA4 apt -STAT3 siRNA treatment of B16 melanoma enhanced antigen-specific adaptive immune responses to endogenous tumor antigens, p15E and TRP-2, compared with CTLA4 apt -LUC siRNA, vehicle control, or CD8 + T cells alone, as measured by IFN-γ production ( Figure 2E) . Furthermore, CTLA4 apt -STAT3 siRNA treat- into tumor-associated T cells expressing CTLA4, including exhausted CD8 + T cells and Tregs as well as malignant T cells. CTLA4 apt -siRNA treatment enables silencing of intracellular checkpoints that are difficult to target with antibodies and small-molecule drugs. CTLA4 apt -STAT3 siRNA treatments improve endogenous adaptive effector functions and induce direct tumor cell killing. While only STAT3 as a therapeutic target in CTLA4-positive cells was tested in the current study, it is anticipated that the CTLA4 apt -siRNA conjugates are applicable for other checkpoints and immunosuppressive molecules in tumor-associated T cells and in CTLA4-expressing malignant cells.
Using an antagonistic aptamer recognizing human CD4, Lieberman and colleagues recently demonstrated interrupted HIV transmission and desired RNAi-mediated knockdown of viral genes by CD4 apt -siRNA chimeras (20) . In these studies, the CD4 apt -siRNA conjugate targeted all CD4 + T cell populations, the primary cellular target of HIV. In contrast, the immunosuppressive tumor microenvironment drives CD8 + T cells into exhaustion and promotes Tregs, both of which are associated with expression of inhibitory coreceptors, including CTLA4 and PD-1. Thus, our studies demonstrate the ability to target specific subsets of T cells -tumor-associated CD8 + T cells and Tregs. While its expression is associated with CD8 + T cell exhaustion, CTLA4 intracellular signaling has been reported to possess a broad plasticity of cellular responses ranging from inhibition of cytokine production and blunting clonal expansion to T cell survival (28, 35, (41) (42) (43) . In our prior investigations, we validated that STAT3 critically contributes to the inhibition of adaptive antitumor immune responses (6, 9) . These observations provided a previously unexplored opportunity to selectively target tumor-associated exhausted CD8 + T cell populations to restore effector functions and augment an antigen-specific CTL population by directed STAT3 gene silencing.
CTLA4 apt -siRNA conjugates preferentially undergo cellular internalization in CD4 + and CD8 + T cells. However, the conjugates are also found in macrophages and dendritic cells to a lesser extent, which potentially could support the adaptive antitumor immune response through STAT3 knockdown in antigen-presenting cells. The uptake by antigen-presenting cells of aptamer-siRNA was also observed in the study using the CD4 + aptamer-siRNA, which seemed to contribute to the efficacy of the chimera in vivo (20) . Furthermore, CTLA4 apt -STAT3 siRNA treatments, administered locally or systemically, tremendously reduce CD4 + CD25 + FoxP3 + Treg populations in primary tumors as well as in melanoma lung metastases, indicating modulation of the tumor immunologic environment in favor of an increased antitumor capability by CD8 + T cells. In mouse tumor models, CTLA4 apt -STAT3 siRNA administration shows a robust inhibition of tumor growth and metastasis. However, CTLA4 apt alone, reported to efficiently block CTLA4, did not improve CTL effector function or impact Treg populations Furthermore, internalization of CTLA4 apt -siRNA by malignant human CTLA4 + T cell lymphoma cells was dose and time dependent, as shown by flow cytometry ( Figure 6D ). To assess in vivo knockdown efficiency by CTLA4 apt -siRNA in human T cell lymphomas, we treated Karpas299 luc+ tumors in a xenograft model with CTLA4 apt -LUC siRNA. Compared with treatment with CTLA4 apt alone, the bioluminescent signal was reduced by over 2-fold upon local administration of CTLA4 apt -LUC siRNA (Figure 6E) , indicating a specific and robust in vivo target knockdown.
CTLA4 apt -STAT3 siRNA inhibits human lymphoma tumor growth. It was previously demonstrated that many types of blood malignancies, including T cell lymphomas, exhibit high CTLA4 expression (39) . We therefore tested the feasibility of blocking STAT3 in T cell lymphoma cells with CTLA4 apt linking to a human STAT3 siRNA and its potential antitumor effects. Immunohistochemical staining of human T cell lymphoma tissue sections indicated upregulated CTLA4 expression relative to normal LNs ( Figure 7, A and B) . Treating Karpas299 human T cell lymphoma engrafted in immunodeficient mice resulted in potent tumor growth inhibition ( Figure 7C ). Tumor growth inhibition was associated with a drastic decrease in STAT3 activation and induction of tumor cell apoptosis ( Figure  7D ). Additionally, we observed decreased proliferation, reduced tumor vasculature, and reduced B7-H1 expression ( Figure 7E ).
Discussion
Given the established role of STAT3 in regulating T cell-mediated cancer progression (6, 7, 9, 40) , cell-selective targeted therapeutic strategies to inhibit STAT3 activation in T cells are of tremendous interest for future immunotherapies. In the current study, we describe an aptamer-based system to selectively deliver siRNA CTLA4 apt -STAT3 siRNA is effective in inhibiting tumor growth. Growth kinetics for melanoma tumor (upper left panel), renal cell carcinoma (upper right panel), lymphoma (lower left panel), and colon carcinoma (lower right panel) assessed upon local administration of CTLA4 apt conjugates or control every other day. SD is shown. *P < 0.05; **P < 0.01; ***P < 0.001.
Besides tumor-associated T cell populations, malignant T cell lymphoma and other blood malignancies also express CTLA4 (47) (48) (49) . Many of these blood malignancies also display elevated STAT3 activation (50) (51) (52) (53) . In nonmalignant T cells, CTLA4 oligomerization on the cell surface readily accumulating in the immunological synapse is considered to depend on ligand activation and therefore represents a biologically active form of CTLA4 (36, 54, 55) . CTLA4 has also been reported to exist at least dimerized prior to ligation in the tumor. This is likely due to the fact that CTLA4 apt used by Gilboa and colleagues (23) was assembled into tetrameric forms of higher antagonistic activity, while STAT3 siRNA was synthetically fused to a monomeric CTLA4 apt . However, due to the lethal hyperimmune phenotype of Ctla4 knockout mice (44, 45) and certain adverse events in patients treated with CTLA4-blocking antibodies (24, 46) , an aptamer with additional potent effects antagonizing CTLA4 in the siRNA conjugate may not be necessary. reduced STAT3 activation. Compared with antagonistic antibodies targeting immune checkpoints, the CTLA4 apt -siRNA chimera additionally directly reduces tumor cell growth and tumor immunosuppressive impact on the T cells in the tumor microenvironment. (55, 56) , indicating the possibility that CTLA4 oligomerizes in a ligand-independent manner in human T cell lymphoma. However, our results indicate that CTLA4 apt -STAT3 siRNA efficiently inhibits T cell lymphoma growth concomitant with considerably
Figure 7
Treating human T cell lymphoma with CTLA4 apt -STAT3 siRNA inhibits tumor growth. (A) Human T cell lymphoma tissue array was stained for CTLA4 expression and analyzed by direct immunofluorescence and (B) quantified (all n = 3). Magnified areas (dashed line) are shown in the lower left corner. Scale bar: 100 μm. Insets were generated in silico by a digital zoom of the indicated regions of interest. SD is shown. **P < 0.01; ***P < 0.001, t test. (C) Tumor growth kinetics of Karpas299 T cell lymphoma engrafted into athymic nude mice treated every other day with CTLA4 apt -STAT3 siRNA, CTLA4 apt -LUC siRNA, or vehicle. (D) Flow cytometry showing phospho-STAT3 expression and apoptotic cell death in the human T cell lymphoma tumors treated as indicated. (E) Human T cell lymphoma tumor microsections prepared from mice treated as indicated were stained for Ki67 + proliferative activity (upper panels), CD31 + tumor vasculature (middle panels), and B7-H1 + (lower panels). Scale bars: 100 μm. Fluorescent signals of Ki67 (n = 5) and B7-H1 (n = 4), and CD31 + (n = 5) blood vessel length assessed by confocal microscopy were quantified from independent fields of view; bar graph shows CTLA4 apt -STAT3 siRNA (light gray), CTLA4 apt -LUC siRNA (dark gray), or vehicle (PBS, black). SD is shown. **P < 0.01; ***P < 0.001, 2 tailed Student's t test.
orophore-coupled antibodies to CD3, CD4, CD8, CD11b, CD11c, CD19, CD25, CD45, F4/80, CTLA4, phospho-Tyr705-Stat3, and IL-10 (BD Biosciences). Annexin V-FITC was purchased from BioVision. Fluorescence data were collected on Accuri (BD Accuri C6) and analyzed using FlowJo software (Tree Star).
Immunoblotting, immunoprecipitation, cytokine array, and ELISA. Whole-cell lysates were prepared using RIPA lysis buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 1 mM NaF, 15% glycerol, and 20 mM β-glycerophosphate. A protease inhibitor cocktail was added fresh to the lysis buffer (Mini Protease Inhibitor Cocktail; Roche). Normalized protein amounts were subjected to electrophoretic separation by SDS-PAGE and transferred onto nitrocellulose for Western blotting; subsequently, immunodetection was performed using antibodies against CTLA4, STAT3 (Santa Cruz Biotechnology Inc.), and β-actin (Sigma-Aldrich). For coimmunoprecipitation, anti-FITC antibody (Invitrogen) was used to label protein G agarose beads (Invitrogen), which were subsequently incubated for 16 hours with whole-cell lysates, subjected to electrophoretic protein separation and Western blot detection. For determination of cytokine-expression profiles, supernatants of fibrosarcoma 8101Re and 8101Pro were collected from a 24-hour cell culture. Tumor cell supernatants were subjected to cytokine arrays and analyzed according to the manufacturer's instructions (RayBiotech). IL-6 cytokine production by fibrosarcoma 8101Re and 8101Pro was determined from a 24-hour cell culture as described above and analyzed according to the manufacturer's instructions (eBioscience).
PCR and ChIP. Transcript amplification was determined from total RNA purified using RNeasy Kit (QIAGEN). cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad). Real-time PCR was performed in triplicate using the Chromo4 Real-Time Detector (Bio-Rad). The murine Gapdh housekeeping gene was used as an internal control to normalize target gene mRNA levels. Primers were obtained from SA Biosciences (mouse Stat3: PPM04643E-200; mouse Il6: PPM03015A-200).
ChIP was performed using the ChIP Assay Kit (Upstate Biotechnology) according to the manufacturer's protocol. Briefly, more than 5 million negatively isolated splenic CD8 + T cells pretreated with 20 ng/ml IL-6 (Peprotech) were fixed with 1% formaldehyde at 37°C for 10 minutes and lysed in ChIP-lysis buffer. We incubated the sonicated chromatin solutions with 4 μg of Stat3 antibodies (Santa Cruz Biotechnology Inc.) or with control rabbit IgG. Following immunoprecipitation and reversed crosslinking, DNA was extracted and analyzed by PCR using the following primer sets for mouse PD-1 promoter: 5′-GGATTCCCGTCCCTCGGTCTC-3′ (forward) and 5′-GGGCCAAGGCGCTTGGCACAG-3′ (reverse).
Statistics. Statistical analyses were performed using Prism (Graph-Pad) software. The overall significance for each graph was calculated using 2-tailed Student's t test. Data represent average ± SD. P values of less than 0.05 were considered statistically significant.
Study approval. Mouse care and experimental procedures with mice were performed under pathogen-free conditions in accordance with established institutional guidance and approved protocols from the Research Animal Care Committees of City of Hope.
